Oric Pharmaceuticals Inc

NASDAQ ORIC

Data sourced from

and

Download Data

Oric Pharmaceuticals Inc Accounts Payable Turnover Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Oric Pharmaceuticals Inc Accounts Payable Turnover Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Oric Pharmaceuticals Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.00, a 0.00% change year over year.
Oric Pharmaceuticals Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.00, a 0.00% change year over year.
Oric Pharmaceuticals Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.00, a 0.00% change year over year.
Oric Pharmaceuticals Inc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.00.

NASDAQ: ORIC

Oric Pharmaceuticals Inc

CEO	Dr. Richard A. Heyman Ph.D.
IPO Date	April 24, 2020
Location	United States
Headquarters	240 East Grand Avenue, South San Francisco, CA, United States, 94080
Employees	102
Sector	Healthcare
Industry	Biotechnology

Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Key trends